Abstract
Introduction/Aim: Patients on methadone maintenance therapy often use psychoactive substances (nicotine, alcohol, cannabis, cocaine, amphetamine-type stimulants, sedatives, hypnotics, hallucinogens and others), which can negatively affect therapeutic outcomes. The aim of this study was to determine the prevalence and pattern of psychoactive substance use among patients on methadone maintenance therapy. Methods: The study was conducted in the Methadone Center of the University Clinical Center of Vojvodina in the period August-October 2022. Substance use data were collected through general and ASSIST (The Alcohol, Smoking and Substance Involvement Screening Test) questionnaires, respectively. Descriptive statistics was used to analyze the collected data. Results: In total, 60 patients on methadone maintenance therapy were included in the study. Among them, the prevalence of the use of nicotine, alcohol and illicit psychoactive substances was 98.3%, 10% and 5.1%, respectively, in the last 3 months preceding the investigation. The use of illicit psychoactive substances was mostly occasional. Three patients had ASSIST score >27 which was associated with a high risk of developing dependence to alcohol (two patients) or cannabis (1 patient). Conclusion: The study indicated a significant difference in the prevalence of the use of licit and illicit psychoactive substances. Therefore, their use should be monitored through regular and occasional urinalysis.
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Reference32 articles.
1. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2023: Trends and Developments. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, 2023. (Available at https:// www.emcdda.europa.eu/publications/european-drugreport/2023_en) 3;
2. Lim J, Farhat I, Douros A, Panagiotoglou D. Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials. PLoS One. 2022;31;17(3): e0266142. doi: 10.1371/journal.pone.0266142;
3. McBrien H, Luo C, Sanger N, Zielinski L, Bhatt M, Zhu XM, et al. Cannabis use during methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis. CMAJ Open. 2019;7(4):E665-E673. doi: 10.9778/cmajo.20190026;
4. Charoensakulchai S, Onwan M, Kanchanasurakit S, Flaherty G, Matsee W. Recreational substance use among international travellers. J Travel Med. 2024 ;31(4):taae012. doi: 10.1093/jtm/taae012. PMID: 38236178;
5. Scott TM, Arnsten J, Olsen JP, Arias F, Cunningham CO, Mindt MR. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/ naloxone in opioid treatment programs. Addict Sci Clin Pract 2021;16(1):64. doi: 10.1186/s13722-021-00272-4;